Premium
CGS 12970: a novel, long acting thromboxane synthetase inhibitor
Author(s) -
Ambler John,
Butler Keith D.,
Ku Edmond C.,
Maguire Eric D.,
Smith James R.,
Wallis Robert B.
Publication year - 1985
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1985.tb08920.x
Subject(s) - platelet , ex vivo , thromboxane a2 , thromboxane , thromboxane b2 , thromboxane a synthase , cyclooxygenase , medicine , chemistry , in vivo , endocrinology , prostacyclin , prostaglandin , arachidonic acid , pharmacology , in vitro , biochemistry , biology , enzyme , microbiology and biotechnology
1 CGS 12970 is a potent selective inhibitor of human platelet thromboxane synthestase in vitro (IC 50 = 12 nM). It is four orders of magnitude less potent as an inhibitor of sheep seminal vesicle cyclo‐oxygenase, bovine aorta prostacyclin synthetase and human leucocyte 15‐lipoxygenase. 2 The compound inhibited collagen‐induced thromboxane B 2 production by human platelets in vitro without an effect on the accompanying platelet aggregation induced by collagen, ADP, platelet activating factor, thrombin, arachidonic acid or the prostaglandin mimetic, U 46619. 3 Administration of CGS 12970 to rats inhibited collagen‐induced thromboxane B 2 production but had no effect on platelet aggregation ex vivo . It also had no effect on platelet aggregation induced by thrombin or on plasma clotting times. 4 A single oral dose of 1 or 3 mg kg −1 to rabbits inhibited thromboxane B 2 production in clotting blood ex vivo for 12 or 24 h respectively. 5 CGS 12970 inhibited thromboxane B 2 production in vivo induced by intravenous administration of collagen to rats or calcium ionophore to guinea‐pigs. In both cases there was a concomitant elevation of immunoreactive 6‐keto‐prostaglandin F 1α but no effect on the induced thrombocytopenia. 6 As with other thromboxane synthetase inhibitors, CGS 12970 prolonged tail bleeding time in the rat. However, CGS 12970 was not as potent as other thromboxane synthetase inhibitors in this test. 7 In addition to these usual effects of thromboxane synthetase inhibitors, CGS 12970 inhibited the thrombocytopenia induced by the Forssman reaction or ADP administration. In these tests the effect of the compound was of short duration. 8 CGS 12970 had no effect on the thrombocytopenia associated with the Arthus reaction which distinguishes it from cyclo‐oxygenase inhibitors. It also had no effect on thrombus formation on a cotton thread in an arteriovenous shunt in the rat.